This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The boom in digital tech over COVID means that pharma can move faster than ever – but the industry’s traditional processes for asset approval are still holding timelines back. David Reily examines how pharma companies are responding to the increased burden of asset approval with new ways of working. The coronavirus pandemic has forced a traditionally risk-averse industry tied to legacy systems for regulation and compliance to fully embrace digital solutions in commercial and marketing functions.
Below is a Q&A with Mark Bard, Co-Founder of The DHC Group, who offers his insights on the challenges COVID-19 has brought to pharma, as well as what innovation is taking place due to this full shift to digital and what lies ahead in the future. What is the most challenging aspect of COVID-19 for the industry? Mark Bard: I think the most challenging aspect of the current situation is the inability of anyone – patient, physician, payor, or pharma – to truly predict how long it will take for v
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Patients with heart failure often have a dismal prognosis as the condition usually worsens over time, but a new study aims to see if digital health technologies can improve their prospects. The trial – run by Boehringer Ingelheim and Yale University – will test a smart bathroom scale device that has cardiac monitoring built in, as well as an app to help patients improve their diet and lose weight and a digital assistant designed to motivate them to actively manage their health.
Co-Founder of The DHC Group, Mark Bard, held a 20-minute expert panel discussion on HCP Communication Innovation, focusing on how COVID-19 is accelerating the shift to digital in pharma marketing, what we are witnessing and what we are learning in the process. 1. COVID-19 is accelerating pharma’s shift to digital and changing the way it engages with HCPs.
Co-Founder of The DHC Group, Mark Bard, held a 20-minute expert panel discussion on HCP Communication Innovation, focusing on how COVID-19 is accelerating the shift to digital in pharma marketing, what we are witnessing and what we are learning in the process. 1. COVID-19 is accelerating pharma’s shift to digital and changing the way it engages with HCPs.
Ayming Group’s second annual International Innovation Barometer (IIB) has said that the international outlook for R&D is “remarkably promising” despite strong headwinds caused by COVID-19. The report reveals that R&D departments are being empowered by the creation of ‘innovation ecosystems’, new funding methods, and the deployment of technology.
Histoplasmosis is an inflammatory lung infection that usually occurs when a human has had contact with bird or bat droppings. Histoplasmosis is similar in symptoms to COVID-19, such as shortness of breath, fever, chest pain, and coughing. Some people who are at high-risk for histoplasmosis may also be concerned that they have contracted COVID-19. Though.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
In the age of artificial intelligence, no trial data should be going to waste. Findacure’s Rick Thompson looks at how these technologies could bring us closer to treatments for underserved rare diseases. The repurposing of drugs is becoming more common, especially in the field of rare diseases. In the past, repurposing has mostly been driven by academics looking for new possibilities in generics.
The pharmaceutical firmâs More to uS is a UK-centered campaign that shares stories of people living (and thriving) after a multiple sclerosis diagnosis.
Pre-Interview Tips for Pharmacy Professionals | Tip #3 with Tom Alig | Vice President of Staffing at Indispensable Health Hi, I am Tom Alig, VP of Staffing with Indispensable Health. I’ve been recruiting pharmacists and pharmacy technicians since 2004, and I’ve seen the things good candidates do to separate themselves, and I’ve seen the mistakes that some candidates make.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
A lack of clear information on COVID risk is stopping people with long-term conditions accessing the care they need – and could be storing up problems for the future. People living with long-term health conditions have been missing vital tests and monitoring because they fear contracting the novel coronavirus. A survey carried out by the Patient Information Forum (PIF), and supported by Norgine, this summer found that almost one in three respondents had delayed accessing care during the pandemic
This might be one of my biggest pet peeves. Adding a medication when we are already doing the opposite with another medication. I had a patient a while back who was taking cholestyramine twice daily for constipation. The patient and caregivers were unclear why the patient was on it but was noting that constipation was […]. The post Pet Peeve Alert: Can We Have a Constipation Medication?
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
UK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen to spearhead the next stage in the company’s development into gene silencing and other areas. Since it was founded in 2001 the company has become one of the country’s best known biotechs thanks to its approach to designing drugs based around network biology. e-therapeutics aims to design drugs that work across several targets that drive complex diseases and its remit has ch
Why do patients stop taking medications? I’ve spent a lot of time and effort working with patients to improve their drug therapy, but it really doesn’t matter if they don’t actually take the medication that is best for them. Here’s a list of the most common reasons that patients stop taking their medication(s). To be […]. The post Why Do Patients Stop Taking Medications?
Sanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after reporting that it stimulated antibodies against SARS-CoV-2 in preclinical testing. The French drugmaker’s Sanofi Pasteur vaccines division says it is planning a phase 1/2 trial of the mRNA-based vaccine, called MRT5500, before the end of the year.
It is estimated that around 103,800 of people live with HIV in the UK (PHE, 2019). Estimated 17% of people with HIV are not aware of the infection (NICE, 2016), increasing the risk of passing HIV when having sex without protection. Truvada (emtricitabine/tenofovir disoproxil) is an antiviral drug used in the treatment of HIV, alone or as part of antiviral combination therapy.
There is growing evidence that the coronavirus may be able to re-infect patients, and a new instance of a second infection has been confirmed in the US. . It is the fifth confirmed reinfection worldwide after at least four other cases were confirmed in Belgium, the Netherlands, Hong Kong and Ecuador. The latest case was recorded in the Lancet Infectious Diseases journal and involved a 25 year-old man with no known immune disorders or underlying conditions.
Several factors can impact breast milk supply with common factors including low frequency of breastfeeding, wrong latching by a baby, late start of breastfeeding, use of formula alongside breastfeeding and some drugs. Drug therapy to increase milk production is usually considered when insufficient milk is produced despite appropriate lactation support (Grzeskowiak et al, 2018).
There has been a well-publicised boom in biotech investment during the pandemic, and the UK is no exception, with a record £1 billion raised in the third quarter. Latest figures from the BioIndustry Association representing the UK’s biotech and life sciences sector, showed it raised more than £1 billion in equity finance between June and August, the highest in the sector on record.
The company's Spectus and Percepta platforms offer features to help researchers meet challenges associated with working and collaborating in the pandemic.
44
44
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
131 
Let's personalize your content